Skip to content
  • KOSPI 2687.44 +31.11 +1.17%
  • KOSDAQ 869.72 +12.90 +1.51%
  • KOSPI200 364.48 +3.46 +0.96%
  • USD/KRW 1377.5 -1.5 -0.11%
  • JPY100/KRW 883.72 +12.4 +1.42%
  • EUR/KRW 1476.4 +1.84 +0.12%
  • CNH/KRW 189.98 +0.28 +0.15%
View Market Snapshot
Bio & Pharma

Samsung invests in BrickBio in US

With Samsung Life Sciences Fund, the group will foster new technologies in ADCs and gene therapeutics

By Mar 19, 2024 (Gmt+09:00)

1 Min read

Samsung　Bioepis　Songdo　headquarters
Samsung　Bioepis　Songdo　headquarters

Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technologies company BrickBio.

The Samsung Life Science Fund is a venture investment fund jointly formed by Samsung C&T Corp., Samsung Biologics Co., and Samsung Bioepis in 2021.

This is the fifth investment of the fund.

According to Samsung, the size of the deal is undisclosed because it's an investment and not an acquisition of control.

Antibody-drug conjugates (ADCs) are emerging as next-generation anticancer drugs that have attracted global attention.

Samsung plans to explore new bio business opportunities such as ADCs and adeno-associated viruses (AAVs) using BrickBio's proprietary artificial amino acid-based conjugation technology.

Write to Dae-Kyu Ahn at powerzani@hankyung.com
#Samsung Life Sciences Fund #US #BrickBio #ADC #gene therapy
More to Read
Comment 0
0/300